BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zoledronic acid readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zoledronic acid\, from ClinicalTrials.gov
  estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02508038-6494@assetmemo.bio
DTSTAMP:20261121T005222Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Zoledronic acid: Phase 1 readout est. (NCT02508038)
DESCRIPTION:Zoledronic acid\, phase 1.\nStudy: Alpha/Beta CD19+ Depleted Ha
 ploidentical Transplantation + Zometa for Pediatric Hematologic Malignanci
 es and Solid Tumors\nEstimated primary completion: December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/zoledronic-acid#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT02508038
URL:https://assetmemo.bio/drug/zoledronic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06513624-6494@assetmemo.bio
DTSTAMP:20261121T005222Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Zoledronic acid: Phase 1 readout est. (NCT06513624)
DESCRIPTION:Zoledronic acid\, phase 1.\nStudy: ETC-159 In Combination With 
 Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers\nEstimated primary comp
 letion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/zoledronic-acid#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06513624
URL:https://assetmemo.bio/drug/zoledronic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05655013-6494@assetmemo.bio
DTSTAMP:20261121T005222Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Zoledronic acid: Phase 4 readout est. (NCT05655013)
DESCRIPTION:Zoledronic acid\, phase 4.\nStudy: Treatment With Zoledronate S
 ubsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2)\nEstimated primary co
 mpletion: 1 February 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/zoledronic-acid#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05655013
URL:https://assetmemo.bio/drug/zoledronic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05053750-6494@assetmemo.bio
DTSTAMP:20261121T005222Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:Zoledronic acid: Phase 1 readout est. (NCT05053750)
DESCRIPTION:Zoledronic acid\, phase 1.\nStudy: TAME: A Pilot Study of Weekl
 y Paclitaxel\, Bevacizumab\, and Tumor Associated Macrophage Targeted Ther
 apy (Zoledronic Acid) in Women With Recurrent\, Platinum-resistant\, Epith
 elial Ovarian\, Fallopian Tube or Primary Peritoneal Cancer\nEstimated pri
 mary completion: 2 February 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/zoledronic-acid#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05053750
URL:https://assetmemo.bio/drug/zoledronic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07753317-6494@assetmemo.bio
DTSTAMP:20261121T005222Z
DTSTART;VALUE=DATE:20270207
DTEND;VALUE=DATE:20270208
SUMMARY:Zoledronic acid: Phase na readout est. (NCT07753317)
DESCRIPTION:Zoledronic acid\, phase na.\nStudy: Clinical and Radiographic E
 valuation of Subgingival 1% Metformin Gel Versus 0.05% Zoledronate Gel as 
 an Adjunct to MINST of Intrabony Defects in Controlled Type 2 DM\nEstimate
 d primary completion: 7 February 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/zoledronic-acid#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07753317
URL:https://assetmemo.bio/drug/zoledronic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07471516-6494@assetmemo.bio
DTSTAMP:20261121T005222Z
DTSTART;VALUE=DATE:20270225
DTEND;VALUE=DATE:20270226
SUMMARY:Zoledronic acid: Phase 1/2 readout est. (NCT07471516)
DESCRIPTION:Zoledronic acid\, phase 1/2.\nStudy: Zoledronic Acid Treatment 
 in Patients With Congenital Dyserythropoietic Anemia\nEstimated primary co
 mpletion: 25 February 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/zoledronic-acid#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07471516
URL:https://assetmemo.bio/drug/zoledronic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04608630-6494@assetmemo.bio
DTSTAMP:20261121T005222Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Zoledronic acid: Phase 2 readout est. (NCT04608630)
DESCRIPTION:Zoledronic acid\, phase 2.\nStudy: Bone Loss Prevention With Zo
 ledronic Acid or Denosumab in Critically Ill Adults\nEstimated primary com
 pletion: 28 February 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/zoledronic-acid#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT04608630
URL:https://assetmemo.bio/drug/zoledronic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03295981-6494@assetmemo.bio
DTSTAMP:20261121T005222Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Zoledronic acid: Phase 3 readout est. (NCT03295981)
DESCRIPTION:Zoledronic acid\, phase 3.\nStudy: Local Bisphosphonate Effect 
 on Recurrence Rate in Extremity Giant Cell Tumor of Bone\nEstimated primar
 y completion: April 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/zoledronic-acid#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT03295981
URL:https://assetmemo.bio/drug/zoledronic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06221072-6494@assetmemo.bio
DTSTAMP:20261121T005222Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Zoledronic acid: Phase 3 readout est. (NCT06221072)
DESCRIPTION:Zoledronic acid\, phase 3.\nStudy: A Study to Assess the Preven
 tion of Bone-related Events in Patients With Bone Metastases From Malignan
 t Solid Tumors Treated With JMT103 Compared to Zoledronic Acid\nEstimated 
 primary completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/zoledronic-acid#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06221072
URL:https://assetmemo.bio/drug/zoledronic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07741136-6494@assetmemo.bio
DTSTAMP:20261121T005222Z
DTSTART;VALUE=DATE:20270815
DTEND;VALUE=DATE:20270816
SUMMARY:Zoledronic acid: Phase 1 readout est. (NCT07741136)
DESCRIPTION:Zoledronic acid\, phase 1.\nStudy: Pharmacokinetics of Zoledron
 ic Acid in Patients on Dialysis\nEstimated primary completion: 15 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/zoledronic-acid#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0774
 1136
URL:https://assetmemo.bio/drug/zoledronic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07375290-6494@assetmemo.bio
DTSTAMP:20261121T005222Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Zoledronic acid: Phase 1 readout est. (NCT07375290)
DESCRIPTION:Zoledronic acid\, phase 1.\nStudy: Zoledronate to Prevent Bone 
 Health Complications in Pediatric Hematopoietic Stem Cell Transplant Survi
 vors\nEstimated primary completion: January 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/zoledronic-acid#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07375290
URL:https://assetmemo.bio/drug/zoledronic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06859580-6494@assetmemo.bio
DTSTAMP:20261121T005222Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Zoledronic acid: Phase 4 readout est. (NCT06859580)
DESCRIPTION:Zoledronic acid\, phase 4.\nStudy: Bisphosphonate Prior to Para
 thyroidectomy in Primary Hyperparathyroidism\nEstimated primary completion
 : 1 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zo
 ledronic-acid#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06859580
URL:https://assetmemo.bio/drug/zoledronic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06762730-6494@assetmemo.bio
DTSTAMP:20261121T005222Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Zoledronic acid: Phase 4 readout est. (NCT06762730)
DESCRIPTION:Zoledronic acid\, phase 4.\nStudy: Zoledronic Acid for the Prev
 ention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naiv
 e HIV Positive Individuals\nEstimated primary completion: 1 December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/zoledronic-acid#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06762730
URL:https://assetmemo.bio/drug/zoledronic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668583-6494@assetmemo.bio
DTSTAMP:20261121T005222Z
DTSTART;VALUE=DATE:20290315
DTEND;VALUE=DATE:20290316
SUMMARY:Zoledronic acid: Phase 2 readout est. (NCT07668583)
DESCRIPTION:Zoledronic acid\, phase 2.\nStudy: EFFICACY AND SAFETY OF ZOLED
 RONATE VERSUS PLACEBO ON PAIN AT WEEK 12 IN PEDIATRIC PATIENTS WITH CHRONI
 C RECURRENT MULTIFOCAL OSTEOMYELITIS\nEstimated primary completion: 15 Mar
 ch 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/zoledronic-a
 cid#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07668583
URL:https://assetmemo.bio/drug/zoledronic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06625190-6494@assetmemo.bio
DTSTAMP:20261121T005222Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Zoledronic acid: Phase 1/2 readout est. (NCT06625190)
DESCRIPTION:Zoledronic acid\, phase 1/2.\nStudy: Alpha/Beta T and B Cell De
 pletion With Zoledronic Acid for Solid Tumors\nEstimated primary completio
 n: February 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zol
 edronic-acid#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06625190
URL:https://assetmemo.bio/drug/zoledronic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06059222-6494@assetmemo.bio
DTSTAMP:20261121T005222Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Zoledronic acid: Phase 4 readout est. (NCT06059222)
DESCRIPTION:Zoledronic acid\, phase 4.\nStudy: The Optimised Use of Romozos
 umab Study\nEstimated primary completion: 31 August 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/zoledronic-acid#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06059222
URL:https://assetmemo.bio/drug/zoledronic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06767150-6494@assetmemo.bio
DTSTAMP:20261121T005222Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Zoledronic acid: Phase 4 readout est. (NCT06767150)
DESCRIPTION:Zoledronic acid\, phase 4.\nStudy: StrAtegies For Zoledronic Ac
 id Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis\nEstimate
 d primary completion: October 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/zoledronic-acid#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06767150
URL:https://assetmemo.bio/drug/zoledronic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
